HEMOPHILIA TREATMENT MARKET ANALYSIS

Global Hemophilia Treatment Market: Key Developments

In January 2023, World Federation of Hemophilia (WFH), U.S. Food and Drug Administration (FDA), proposed individual risk assessment for blood donations in revision of U.S.A. donor eligibility and deferral policies. WFH Gene Therapy Registry (GTR) aims to collect important data on all patients who have received gene therapy either through clinical trials or post-marketed product.

In April 2020, the U.S. Food and Drug Administration approved HEMA Biologics’s, biopharmaceutical company’s sevenfact coagulation factor VIIa (recombinant)-jncw) for the adults and adolescents of 12 years of age and older with hemophilia A or B.

In May 2022, Takeda Biopharmaceutical company, announced the expansion of its rare diseases portfolio in developing countries like India with the launch of Adynovate, an innovative extended half-life recombinant Factor VIII treatmentthat uses established technology for treating hemophilia A patients.